Poseida Therapeutics, Inc. Deferred Tax Assets, in Process Research and Development

Poseida Therapeutics, Inc. Deferred Tax Assets, in Process Research and Development

Poseida Therapeutics, Inc. had Deferred Tax Assets, in Process Research and Development of $39.34 million as of 2023-12-31, per its 10-K filed 2024-03-07.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross

us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2024-03-07

• 2023-12-31: Deferred Tax Assets, in Process Research and Development $39.34M.
• 2022-12-31: Deferred Tax Assets, in Process Research and Development $23.37M.